Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Microfluidics Market to Reach US$ 43 Bn by 2031, Growing at 9.8% CAGR as Point-of-Care and Organ-on-Chip Adoption Expands: New Report by Wissen Research

prnewswire.com
TMO Thermo Fisher Scientific Inc. is identified as a leading company in the microfluidics market, focusing on life science instruments and consumables. The article highlights the overall market growth and technological advancements, positioning Thermo Fisher as a key player within this expanding sector. ILMN Illumina, Inc. is listed as a key player in the microfluidics market, with a focus on sequencing and library preparation platforms. The company's involvement suggests it benefits from the overall market growth and technological advancements in areas like single-cell analysis. BIIB Bio-Rad Laboratories, Inc. is recognized as a leading company in the microfluidics market, specializing in life science research and clinical diagnostics. Its position indicates potential benefits from the expanding adoption of microfluidic technologies in these fields. DHR Danaher Corporation is identified as a key player in the microfluidics market, focusing on diagnostics and life sciences instrumentation. The company is well-positioned to capitalize on the projected growth and increasing demand for microfluidic solutions. BDX Becton, Dickinson and Company is named as a leading player in the microfluidics market, focusing on diagnostic instruments and consumables. The company's involvement suggests it is well-positioned to benefit from the growth in point-of-care testing and diagnostics. ABT Abbott Laboratories is identified as a leading company in the microfluidics market, with a focus on diagnostics and point-of-care testing. The article indicates that Abbott is well-positioned to benefit from the increasing demand for decentralized diagnostics.

Microfluidics Market to Reach US$ 43 Bn by 2031, Growing at 9.8% CAGR as Point-of-Care and Organ-on-Chip Adoption Expands: New Report by Wissen Research SHERIDAN, Wyo., Sept. 28, 2026 /PRNewswire/ -- The global microfluidics market is projected to grow from USD 26.9 billion in 2026 to USD 43 billion by 2031, registering a CAGR of 9.8% during the forecast period (2026–2031), according to a new study by Wissen Research.

Growth is being driven by rising demand for point-of-care testing and decentralized diagnostics, expanding use of precision medicine, and sustained pharmaceutical and biotech investment in organ-on-a-chip and droplet-based single-cell systems. Microfluidic platforms handle liquids at the microliter and nanoliter scale inside engineered channels, which cuts sample and reagent volumes, speeds up analysis, and moves testing closer to the patient, the research bench, and the field.

Get a Free Sample of This Report to Explore Key Findings and Data: https://www.wissenresearch.com/request-a-sample/?report=microfluidics-market

Where the Technology Is Heading: Integrated Chips, Smarter Readers

The most visible shift in microfluidics is the move from single-function chips, which run one test, to fully integrated sample-to-answer cartridges that combine sample preparation, amplification, and detection on a single chip. Manufacturers are extending chip integration into multifunctionality and coupling the hardware with AI-driven analysis software, allowing platforms once confined to specialized labs to operate in clinical and field environments.

Machine-learning algorithms are increasingly built into handheld and benchtop readers to analyze fluorescence, morphology, and other optical signals, supporting automated interpretation, quantitative output, and the standardized data capture and traceability that regulated diagnostic workflows require.

In pharmaceutical research, organ-on-a-chip models are gaining ground as a complement to conventional cell and animal-based models in early toxicity and efficacy testing. Multi-organ designs that link several tissue types on one platform are beginning to move from academic proof-of-concept into contract-research service offerings.

What's Fueling Growth in the Microfluidics Market

Challenges Facing the Microfluidics Market

Cost and validation remain the main brakes on adoption. Microfluidic instrumentation carries high initial costs compared with conventional laboratory equipment, and validating new platforms adds further expense, which is particularly difficult for smaller research laboratories and cost-conscious institutions to absorb. Established laboratory procedures also resist change, even where a new format offers clear speed or volume advantages.

Regulation is another source of uncertainty. Frameworks continue to lag technology, especially for organ-chip platforms and multiplex diagnostics, and the treatment of formats designed to complement or reduce reliance on certain animal-based studies is still evolving. That makes long-range product planning harder for manufacturers. Some applications also still require trained personnel, specialized readers, and quality control procedures before clinical deployment.

Recent Strategic Developments in the Microfluidics Market

In August 2026, HyperMelt, a U.S. diagnostics startup, was reported to be developing a microfluidics-based platform that combines sample digitization with thermal analysis to improve molecular characterization of cancer-related biomarkers, with potential applications in early cancer detection and liquid biopsy workflows.

In April 2025, CEA-Leti and Infiplast of France launched a dedicated microfluidics initiative to accelerate the industrialization and manufacturing of healthcare-oriented microfluidic devices, helping move laboratory-developed technologies into commercial products.

In November 2024, Parallel Fluidics secured USD 7 million in seed funding to accelerate its microfluidic manufacturing platform for life science applications including IVF, biotechnology research, and advanced laboratory workflows.

Taken together, these moves point to an industry focused on scaling manufacturing, moving lab-built devices to market, and extending microfluidics into oncology and reproductive health.

Key Insights from Microfluidics Market Analysis

Key Players in the Microfluidics Market

Leading companies in the microfluidics market are focused on product innovation, lab-on-chip platform development, integration of microfluidics with molecular diagnostics and single-cell analysis, strategic collaborations, and manufacturing expansion.

Company

Key Focus Area

Thermo Fisher Scientific Inc. (US)

Life science instruments and consumables

Illumina, Inc. (US)

Sequencing and library preparation platforms

Bio-Rad Laboratories, Inc. (US)

Life science research and clinical diagnostics

Danaher Corporation (US)

Diagnostics and life sciences instrumentation

Agilent Technologies, Inc. (US)

Analytical instruments and life sciences tools

F. Hoffmann-La Roche Ltd (Switzerland)

Diagnostics platforms

bioMérieux (France)

Infectious disease diagnostics

Becton, Dickinson and Company (US)

Diagnostic instruments and consumables

Abbott Laboratories (US)

Diagnostics and point-of-care testing

10x Genomics (US)

Single-cell analysis platforms

Emulate (US)

Organ-on-chip technology

Dolomite Microfluidics (UK)

Droplet and microfluidic systems

Regional Analysis and Growth Opportunities

North America leads the microfluidics market, backed by a strong base of established diagnostics and life science companies, a mature biotechnology ecosystem, significant R&D investment, and a dense network of device manufacturers, component suppliers, and research institutions across major biotech clusters. The region's experience with regulatory pathways for diagnostic technologies further supports commercialization and adoption.

Asia-Pacific is the fastest-growing region, with rising investment in diagnostics and research infrastructure, a growing burden of chronic and infectious disease, and government support for local manufacturing of microfluidic devices. Growing R&D spending and cross-border manufacturing collaborations in China, India, and Japan are positioning the region as an important contributor to global demand.

Europe, Latin America, and the Middle East & Africa complete the report's regional coverage, with growth shaped by expanding diagnostic capacity and rising research investment.

Get a Custom Briefing on This Market for Your Business

Wissen Research's technology analysts are available to walk through findings specific to your market, region, or competitive set.

Need Insights Specific to Your Business? Request a Customized Version of This Report: https://www.wissenresearch.com/request-customization/?report=microfluidics-market

Market Segmentation Snapshot

The global microfluidics market is segmented across product type, material, technology, application, end user, and region:

Frequently Asked Questions

Q: What is the size of the microfluidics market?

A: The global microfluidics market is estimated at USD 26.9 billion in 2026 and is projected to reach USD 43 billion by 2031.

Q: What is the growth rate of the microfluidics market?

A: The microfluidics market is projected to grow at a CAGR of 9.8% between 2026 and 2031.

Q: Which application dominates the microfluidics market?

A: In vitro diagnostics dominates total consumption, covering infectious disease panels, cardiac markers, and molecular point-of-care tests, while pharmaceutical and life sciences research is the fastest-growing application segment.

Q: Which region leads the microfluidics market?

A: North America led the microfluidics market in 2025, while Asia-Pacific is the fastest-growing region through 2031.

Q: What is organ-on-a-chip technology?

A: Organ-on-a-chip devices use microfluidic channels to mimic the mechanical and biochemical conditions of specific human tissues, and pharmaceutical companies use them in early toxicity and efficacy testing to complement conventional cell culture and animal-based models.

Q: Who are the top players in the microfluidics market?

A: Leading players in the microfluidics market include Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, and Agilent Technologies, Inc.

As integrated sample-to-answer cartridges, AI-enabled analytics, and organ-on-a-chip models continue to mature, microfluidics is becoming a core enabling technology across diagnostics, drug discovery, and life science research. For manufacturers, the path forward lies in scalable production, regulatory readiness, and platforms that lower the cost of moving from laboratory to point of care.

Get the Complete Microfluidics Market Report — Forecasts, Insights & Growth Opportunities: https://www.wissenresearch.com/market-research-reports-pricings/microfluidics-market

Expert Profile | Mayur Jain, Wissen Research

Mayur Jain is a Research Expert at Wissen Research with multidomain expertise with more than 12+ years of experience in market research industry.

Email: [email protected]

LinkedIn: https://www.linkedin.com/in/mayur-jain-0190542a/

About Wissen Research

Wissen Research is a global market intelligence and consulting firm specializing in healthcare, life sciences, technology, and emerging industries. The company provides data-driven insights, strategic market analysis, and industry forecasts to help organizations make informed business decisions and identify new growth opportunities across global markets

Company Contact:

Wissen Research LLC,

Gould St, Ste R,

Sheridan, WY 82801,

Phone: (+1) 510 240 9853

Email: [email protected]

Website: https://www.wissenresearch.com/

Blog: https://www.wissenresearch.com/insights/

LinkedIn: https://www.linkedin.com/company/wissen-research

SOURCE Wissen Research LLC